Abbvie Inc.

Thomas E N Jonassen

Bjarne Due Larsen

Soren Nielsen

Jorgen Frokiaer

The invention describes peptide analogues of &#x3b1;-melanocyte-stimulating hormone (&#x3b1;-MSH), which possess an increased efficacy compared to the native &#x3b1;-MSH peptide. The &#x3b1;-MSH analogues exhibit increased anti-inflammatory effects and increased capability to prevent ischemic conditions compared to &#x3b1;-MSH. The invention further discloses use of the peptides for the manufacture of pharmaceutical compositions for the treatment or prophylaxis of a condition in the tissue of one or more organs of a mammal, and moreover pharmaceutical compositions.

Therapeutically active &#x3b1;-MSH analogues

Method for preventing or reducing acute renal failure by administration of therapeutically active &#x3b1;-MSH analogues

The invention describes peptide analogues of a-melanocyte-stimulating hormone (a-MSH), which posses an increased efficacy compared to the native &#x3b1;-MSH peptide. The &#x3b1;-MSH analogues exhibit increased anti-inflammatory effects and increased capability to prevent ischemic conditions compared to &#x3b1;-MSH. The invention further discloses use of the peptides for the manufacture of pharmaceutical compositions for the treatment or prophylaxis of a condition in the tissue of one or more organs of a mammal, and moreover pharmaceutical compositions.

Growing community of inventors

Holte, Denmark

Thomas E N Jonassen